Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Lupo, Maria Giovanna, Arcidiacono, Diletta, Zaramella, Alice, Fimiani, Fabio, Calabrò, Paolo, Cefalù, Angelo Baldassare, Averna, Maurizio, D'Erasmo, Laura, Arca, Marcello, De Martin, Sara, Zambon, Alberto, Ferri, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833247/
https://www.ncbi.nlm.nih.gov/pubmed/36644506
http://dx.doi.org/10.1016/j.athplu.2021.05.001
Descripción
Sumario:Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Ejemplares similares